Notably, the authors demonstrated a reduction of subcutaneous xenograft tumors and extended survival of mice upon treatment with 10 mg/kg of THZ1 and suggested the combination with PIs or B-cell lymphoma 2 (Bcl-2) Homology 3 (BH-3) mimetics, as they observed a significant increase in cell death of primary patient-derived CD138+ cells and MM stem-like cells (CD138-, CD19+, CD20+, CD27+), while having little effect on healthy cord blood cells (CD138-, CD34+)[81]. This evidence concerns the gene SDC1 and Miyoshi myopathy.